Davies F - Search Results

1

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.

Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, Bärtsch MA, Maclachlan K, Chojnacka M, Diamond B, John L, Reichert P, Huhn S, Blaney P, Gagler D, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani S, Landgren O, Raab MS, Weinhold N, Maura F. Cirrincione AM, et al. Among authors: davies f. Blood. 2024 Aug 15;144(7):771-783. doi: 10.1182/blood.2024024299. Blood. 2024. PMID: 38728430

2

The use of biological variables to predict outcome in multiple myeloma.

Davies FE, Jack AS, Morgan GJ. Davies FE, et al. Br J Haematol. 1997 Dec;99(4):719-25. Br J Haematol. 1997. PMID: 9432013 Free article. Review. No abstract available.

3

Controversies surrounding the clonogenic origin of multiple myeloma.

Davies FE, Rawstron AC, Owen RG, Morgan GJ. Davies FE, et al. Br J Haematol. 2000 Jul;110(1):240-1. doi: 10.1046/j.1365-2141.2000.02072-6.x. Br J Haematol. 2000. PMID: 10931011 Free article. No abstract available.

4

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.

Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, Russell NH, Hale G, Morgan GJ, Jack AS, Hillmen P. Rawstron AC, et al. Among authors: davies fe. Blood. 2001 Jul 1;98(1):29-35. doi: 10.1182/blood.v98.1.29. Blood. 2001. PMID: 11418459 Free article.

5

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC. Davies FE, et al. Blood. 2001 Jul 1;98(1):210-6. doi: 10.1182/blood.v98.1.210. Blood. 2001. PMID: 11418482 Free article.

6

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS. Barrans SL, et al. Blood. 2002 Feb 15;99(4):1136-43. doi: 10.1182/blood.v99.4.1136. Blood. 2002. PMID: 11830458 Free article.

7

Minimal residual disease monitoring in multiple myeloma.

Davies FE, Rawstron AC, Owen RG, Morgan GJ. Davies FE, et al. Best Pract Res Clin Haematol. 2002 Mar;15(1):197-222. doi: 10.1053/beha.2002.0192. Best Pract Res Clin Haematol. 2002. PMID: 11987924 Review.

8

Myeloma aetiology and epidemiology.

Morgan GJ, Davies FE, Linet M. Morgan GJ, et al. Among authors: davies fe. Biomed Pharmacother. 2002 Jul;56(5):223-34. doi: 10.1016/s0753-3322(02)00194-4. Biomed Pharmacother. 2002. PMID: 12199621 Review.

9

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ. Rawstron AC, et al. Blood. 2002 Nov 1;100(9):3095-100. doi: 10.1182/blood-2001-12-0297. Blood. 2002. PMID: 12384404 Free article.

10

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.

Ashcroft AJ, Davies FE, Morgan GJ. Ashcroft AJ, et al. Lancet Oncol. 2003 May;4(5):284-92. doi: 10.1016/s1470-2045(03)01076-3. Lancet Oncol. 2003. PMID: 12732166 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

781 results

Search Page

Filters